Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der skal give børn og unge, der har gennemført kliniske undersøgelser, der involverer Gilead-hiv-behandlinger, fortsat adgang til undersøgelse af stof

5. november 2026 opdateret af: Gilead Sciences

Et åbent, enkeltarmsstudie for at give deltagere, der har gennemført pædiatriske kliniske undersøgelser, der involverer Gilead-hiv-behandling, fortsat adgang til lægemiddel

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.

The primary objectives of this study are as follows:

  • To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
  • To evaluate the safety of the study drug(s) in participants with HIV-1.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

350

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, C1141 ACG
        • Afsluttet
        • Helios Salud
      • Panama City, Panama, 0816-00383
        • Afsluttet
        • Hospital del Niño
      • Cape Town, Sydafrika, 7505
        • Rekruttering
        • University of Stellenbosch
      • Durban, Sydafrika, 3629
        • Rekruttering
        • Enhancing Care Foundation
      • Johannesburg, Sydafrika, 2112
        • Rekruttering
        • Rahima Moosa Mother and Child Hospital
      • Johannesburg, Sydafrika, 2038
        • Rekruttering
        • WITS RHI Research Centre
      • Paarl, Sydafrika, 7626
        • Rekruttering
        • Be Part Yoluntu Centre
      • Pretoria, Sydafrika, 0087
        • Rekruttering
        • The Aurun Institute
      • Soweto, Sydafrika, 2013
        • Rekruttering
        • Perinatal HIV Research Unit
      • Bangkok Noi, Thailand, 10700
        • Aktiv, ikke rekrutterende
        • Faculty of Medicine - Mahidol University
      • Khon Kaen, Thailand, 40002
        • Aktiv, ikke rekrutterende
        • Khon Kaen University
      • Kampala, Uganda, 10005
        • Rekruttering
        • Joint Clinical Research Centre
      • Kampala, Uganda, 256
        • Rekruttering
        • MU-JHU Research Collaboration/MU-JHU Care Ltd
      • Kampala, Uganda
        • Rekruttering
        • Baylor College of Medicine
      • Kampala, Uganda
        • Rekruttering
        • Strengthening Institutional Capacity for Research Administration (SICRA)
      • Masaka, Uganda
        • Rekruttering
        • Africa Medical and Behavioral Sciences Organisation
      • Harare, Zimbabwe
        • Rekruttering
        • University of Zimbabwe Clinical Research Centre

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 måned og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.

Key Exclusion Criteria:

  • Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.

    • Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
  • Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.

  • For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.

  • For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.

  • Ongoing treatment with or prior use of any prohibited medications.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF

Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent.

Participants may switch to B/F/TAF, at a dose based on participant's weight.

200/25 mg fixed-dose combination (FDC) tablet administered orally

Andre navne:
  • Descovy®

200/10 mg FDC tablet administered orally

120/15 mg FDC tablet administered orally

50/200/25 mg FDC tablet administered orally

Andre navne:
  • Biktarvy®
  • GS-9883/F/TAF

30/120/15 mg FDC tablet administered orally

Andre navne:
  • GS-9883/F/TAF

15/60/7.52 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country

Eksperimentel: Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF

Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg.

Participants may switch to B/F/TAF at a dose based on participant's weight.

50/200/25 mg FDC tablet administered orally

Andre navne:
  • Biktarvy®
  • GS-9883/F/TAF

30/120/15 mg FDC tablet administered orally

Andre navne:
  • GS-9883/F/TAF

150/150/200/10 mg tablet administered orally

Andre navne:
  • Genvoya®

90/90/120/6 mg tablet administered orally

Eksperimentel: Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF

Participants will continue to take the following study drugs they were taking in the parent study:

  • Cobicistat (COBI) + DRV + NRTI backbone
  • COBI + ATV + NRTI backbone
  • F/TAF + DRV+ COBI
  • F/TAF + ATV+ COBI
  • F/TAF + LPV/r
  • F/TAF + 3rd unboosted agent

The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily.

Participants may switch to B/F/TAF at a dose based on participant's weight.

200/25 mg fixed-dose combination (FDC) tablet administered orally

Andre navne:
  • Descovy®

120/15 mg FDC tablet administered orally

50/200/25 mg FDC tablet administered orally

Andre navne:
  • Biktarvy®
  • GS-9883/F/TAF

30/120/15 mg FDC tablet administered orally

Andre navne:
  • GS-9883/F/TAF

15/60/7.52 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country

60/7.5 mg tablet for oral suspension (TOS) administered orally

30/3.75 mg TOS administered orally

15/1.88 mg TOS administered orally

150 mg tablet administered orally

Andre navne:
  • Tybost®
  • GS-9350

90 mg tablet administered orally

Andre navne:
  • GS-9350

30 mg TOS administered orally

Andre navne:
  • GS-9350

7.5/30/3.76 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

3.76/15/1.88 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)

Administered according to the prescribing information

Administered according to the prescribing information

Administered according to the prescribing information

Eksperimentel: Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)

Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant.

50/200/25 mg FDC tablet administered orally

Andre navne:
  • Biktarvy®
  • GS-9883/F/TAF

30/120/15 mg FDC tablet administered orally

Andre navne:
  • GS-9883/F/TAF

15/60/7.52 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

7.5/30/3.76 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

3.76/15/1.88 mg TOS administered orally

Andre navne:
  • GS-9883/F/TAF

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Tidsramme: Up to 2.8 Years
Up to 2.8 Years

Sekundære resultatmål

Resultatmål
Tidsramme
Procentdel af deltagere, der oplever behandlingsfremkaldte bivirkninger (TEAE'er)
Tidsramme: Op til 9,5 år
Op til 9,5 år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Gilead Study Director, Gilead Sciences

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. august 2024

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. marts 2034

Datoer for studieregistrering

Først indsendt

22. marts 2024

Først indsendt, der opfyldte QC-kriterier

22. marts 2024

Først opslået (Faktiske)

29. marts 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GS-US-380-6684
  • 2024-000521-40 (Anden identifikator: European Medicines Agency)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .